Immunotherapy before lung cancer surgery shows promise in early trial
NCT ID NCT02818920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the immunotherapy drug pembrolizumab in 35 people with early-stage non-small cell lung cancer. Participants received the drug before and after surgery to see if it could help the immune system attack cancer cells. The main goal was to check if surgery could still be done safely after the drug. Results help guide future research, but this treatment is not yet a standard option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill keep lung cancer from returning?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Lab-Made immune protein takes on advanced cancers in first human test
- Experimental combo for lung cancer shows promise but study cut short
- New study tracks how well a targeted lung cancer drug works in everyday clinics
- New 4D scan could sharpen lung cancer radiation